Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2010 2
2012 2
2013 1
2015 2
2016 2
2017 3
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
[Therapeutic update in hepatitis C].
Devesa MJ, Cuenca F, Izquierdo S, Sánchez-Pobre P, Ladero JM, López-Alonso G, Díaz-Rubio M, Rey E. Devesa MJ, et al. Rev Esp Quimioter. 2015 Sep;28 Suppl 1:48-51. Rev Esp Quimioter. 2015. PMID: 26365735 Free article. Review. Spanish.
HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1.
Berenguer J, Calleja JL, Montes ML, Gil Á, Moreno A, Bañares R, Aldámiz-Echevarría T, Albillos A, Téllez MJ, Olveira A, Domínguez L, Fernández I, García-Samaniego J, Polo BA, Álvarez B, Ryan P, Barrio J, Devesa MJ, Benítez L, Santos I, Buey LG, Sanz J, Poves E, Losa JE, Fernández-Rodríguez C, Jarrín I, Calvo MJ, González-García J. Berenguer J, et al. Among authors: devesa mj. Open Forum Infect Dis. 2019 May 7;6(5):ofz214. doi: 10.1093/ofid/ofz214. eCollection 2019 May. Open Forum Infect Dis. 2019. PMID: 31139679 Free PMC article.
Vitamin D deficiency and vitamin D therapy in chronic hepatitis C.
Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA. Ladero JM, et al. Among authors: devesa mj. Ann Hepatol. 2013 Mar-Apr;12(2):199-204. Ann Hepatol. 2013. PMID: 23396730 Free article.
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. Alonso López S, et al. Among authors: devesa mj. Hepatology. 2020 Dec;72(6):1924-1934. doi: 10.1002/hep.31588. Epub 2020 Nov 10. Hepatology. 2020. PMID: 33022803
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, García-Samaniego J, García-Paredes F, Fernández I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro Ríos M, Fernández-Rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P, Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MÁ, Arenas J, Real Y, Jorquera F, Calleja JL; Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs. Perelló C, et al. J Viral Hepat. 2017 Mar;24(3):226-237. doi: 10.1111/jvh.12637. Epub 2016 Dec 15. J Viral Hepat. 2017. PMID: 27976491
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Alonso S, et al. Among authors: devesa mj. J Viral Hepat. 2017 Apr;24(4):304-311. doi: 10.1111/jvh.12648. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935168 Free article.
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, Izquierdo S, Ortiz M, Hernández-Albujar A, Fernández-Rodríguez C, Calvo M, González R, Lozano M, Castellano G, Fernández-Vázquez I. Muñoz-Gómez R, et al. Among authors: devesa mj. J Viral Hepat. 2017 Jun;24(6):464-471. doi: 10.1111/jvh.12664. Epub 2017 Jan 20. J Viral Hepat. 2017. PMID: 27976490
16 results